International Journal of Scientific Research in Science, Engineering and Technology

Print ISSN - 2395-1990
Online ISSN : 2394-4099

Available Online at :www.ijsrset.com
doi : https://doi.org/10.32628/IJSRSET25122103

Advancing Breast Cancer Therapy with Iron Oxide Nanoparticles

Soumitra Mandal

Department of Chemistry, Fakir Chand College, Diamond Harbour- 743331, South 24- Parganas, West Bengal, India

ARTICLEINFO

Article History:

Accepted : 01 March 2025
Published: 04 March 2025

Publication Issue :
Volume 12, Issue 2
March-April-2025

Page Number :
08-26

ABSTRACT

Breast cancer remains a leading cause of morbidity and mortality among women worldwide, presenting a pressing challenge for global health. The integration of nanotechnology into cancer care offers transformative opportunities to improve diagnostics, therapeutic interventions, and monitoring. Among various nanomaterials, iron oxide nanoparticles (IONPs) stand out for their distinctive physicochemical properties, including superparamagnetism, excellent biocompatibility, and the flexibility for surface functionalization. This article delves into the diverse applications of IONPs in breast cancer care, focusing on breakthroughs in imaging modalities, precision-targeted drug delivery systems, and innovative therapeutic strategies. By analyzing the latest research findings and clinical trial data, we present a detailed exploration of how IONPs can significantly advance the landscape of breast cancer management, paving the way for personalized and effective patient care.

Keywords: Iron Oxide Nanoparticles (IONPs), Nanomedicine, Cancer Theranostics, Breast Cancer Care, Targeted Drug Delivery

INTRODUCTION

Breast cancer is the most frequently diagnosed cancer among women globally, accounting for millions of new cases and significant mortality each year [1], [2], [3]. Despite advances in medical technology, traditional diagnostic and therapeutic methods face inherent challenges [4]. These include the lack of specificity in targeting cancer cells, adverse systemic side effects of treatments, and the emergence of therapy-resistant cancer phenotypes. These limitations underscore the urgent need for innovative strategies in breast cancer management [5], [6], [7], [8], [9], [10].

Nanotechnology, particularly the use of iron oxide nanoparticles (IONPs), offers a groundbreaking approach to addressing these challenges. IONPs are distinguished by their unique magnetic properties, enabling their application in multiple domains of cancer care [4], [11], [12], [13], [14], [15]. In magnetic resonance imaging (MRI), they act as efficient contrast agents, improving the accuracy of tumor detection and characterization [4], [15], [16], [17],

Copyright © 2025 The Author(s): This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

[18], [19]. For therapeutic applications, IONPs can be functionalized to deliver drugs directly to cancer cells, minimizing harm to healthy tissues [4], [14], [20], [21], [22], [23]. Moreover, their ability to generate localized heat under an alternating magnetic field has made them a promising tool in hyperthermia therapy, which selectively destroys tumor cells [4], [14], [24], [25], [26], [27].

The versatility and multifunctionality of IONPs have positioned them at the forefront of nanomedicine research. By integrating diagnostics and therapy, they offer a comprehensive approach to tackling breast cancer, providing a foundation for precision medicine and improving patient outcomes [12], [21], [28], [29]. This article explores the advancements, challenges, and future potential of IONPs in revolutionizing breast cancer care.

PROPERTIES OF IRON OXIDE NANOPARTICLES

Iron oxide nanoparticles (IONPs) are primarily composed of magnetite (Fe_3O_4) or maghemite (γ-Fe_2O_3), both of which exhibit unique superparamagnetic properties at the nanoscale. This superparamagnetic behavior enables IONPs to respond efficiently to external magnetic fields, while their lack of residual magnetism after field removal makes them particularly suitable for biomedical applications, minimizing risks of particle aggregation [15], [30], [31]. Iron oxide nanoparticles (IONPs) possess a unique set of physicochemical properties that make them highly advantageous for applications in biomedical science, particularly in breast cancer care. These properties are defined by their magnetic behavior, biocompatibility, surface modifiability, and scalability, among others [32], [33], [34], [35].

Magnetic Properties

IONPs exhibit superparamagnetic behavior at the nanoscale. Unlike ferromagnetic materials, superparamagnetic nanoparticles have no residual magnetism once an external magnetic field is removed. This property minimizes aggregation and ensures stable dispersion in biological environments, making them ideal for applications such as magnetic resonance imaging (MRI) and targeted drug delivery. Additionally, their high magnetic susceptibility allows them to respond efficiently to external magnetic fields, enabling precise manipulation and controlled localization [32], [36], [37], [38], [39].

Biocompatibility

IONPs are inherently biocompatible, particularly when composed of magnetite (Fe3O4) or maghemite (γ-Fe2O3). This biocompatibility can be further enhanced through surface functionalization with biocompatible coatings such as polyethylene glycol (PEG), dextran, or silica. These coatings not only improve stability in biological environments but also reduce immune recognition and potential toxicity [37], [38], [40], [41], [42].

Surface Functionalization

Surface functionalization is critical for enhancing the stability, biocompatibility, and functionality of IONPs. Biocompatible coatings such as polyethylene glycol (PEG), dextran, silica, or chitosan are commonly applied. These coatings not only improve colloidal stability but also provide functional groups for conjugating targeting ligands, such as antibodies, peptides, or small molecules. Functionalization expands the versatility of IONPs, enabling their use in targeted drug delivery, imaging, and therapeutic applications. Functionalization also enhances colloidal stability and prevents nonspecific interactions in complex biological systems [37], [40], [41], [43], [44].

Size and Shape Tunability

IONPs can be synthesized with precise control over their size and shape, which directly influence their magnetic and biological properties. For example, smaller nanoparticles exhibit faster blood clearance, while larger particles have improved magnetic properties for imaging and therapeutic applications. Tailoring size and shape allows customization for specific biomedical applications [21], [41], [44], [45], [46].

Colloidal Stability

In aqueous and biological environments, IONPs demonstrate excellent colloidal stability, particularly when coated with hydrophilic polymers or surfactants. This stability is crucial for their performance in vivo, as it prevents aggregation and ensures uniform distribution in the bloodstream or target tissues [47], [48], [49], [50].

Biodegradability and Clearance

IONPs are biodegradable, with their degradation products being metabolized and excreted through natural pathways. This property reduces long-term toxicity and makes them safer for clinical applications. However, ensuring controlled biodegradation and preventing accumulation in vital organs remain areas of active research [47], [51], [52], [53].

Optical Properties

Some IONPs exhibit optical properties that enable their use in photothermal and photoacoustic imaging. These properties can be further enhanced through doping or surface modification, broadening their applicability in multimodal imaging systems [21], [54], [55], [56].

Scalability and Economic Viability

The synthesis methods for IONPs, such as coprecipitation, thermal decomposition, and hydrothermal synthesis, are scalable and economically feasible. These methods allow the production of high-quality nanoparticles in large quantities, facilitating their translation from laboratory research to clinical applications [57], [58], [59].

SYNTHESIS OF IRON OXIDE NANOPARTICLES

Synthesis of Iron Oxide Nanoparticles has undergone significant advancements to ensure precise control over particle size, shape, and magnetic properties, which are critical for their biomedical applications. Several well-established methodologies are employed, each offering unique advantages and addressing specific challenges.

Coprecipitation

A straightforward and widely employed method that involves the chemical precipitation of iron salts (typically ferrous and ferric ions) in an alkaline medium. This technique stands out for its simplicity, cost-effectiveness, and scalability, making it suitable for industrial applications. However, one of its main limitations is the potential for producing nanoparticles with less uniform size and shape, which can impact their magnetic properties and overall performance. Efforts to improve the uniformity of particles synthesized via coprecipitation include optimizing reaction parameters such as temperature, pH, and ionic strength, as well as the use of stabilizing agents during synthesis to control nucleation and growth processes [60], [61], [62], [63].

Thermal Decomposition

This sophisticated method involves the high-temperature breakdown of organometallic precursors in organic solvents, typically in the presence of stabilizers or surfactants. The process yields nanoparticles with exceptional uniformity, allowing for precise control over their size, shape, and crystallinity. This high level of control is critical for tailoring the magnetic and physical properties of the nanoparticles to meet specific biomedical application requirements. Additionally, the organic solvent medium ensures a clean reaction environment, reducing the likelihood of impurities and facilitating better reproducibility of results. However, the method is resource-intensive and requires careful handling of precursors and solvents, which can be a limitation for large-scale production [64], [65], [66], [67], [68].

Hydrothermal Synthesis

This method involves the use of high-pressure, high-temperature conditions in sealed reactors, typically in an aqueous solution, to produce nanoparticles with superior crystallinity and dispersion. By providing a controlled environment for crystal growth, hydrothermal synthesis allows precise tuning of

particle size, morphology, and phase composition. The technique is particularly advantageous for achieving highly stable and uniform nanoparticles with excellent structural integrity, making it well-suited for applications requiring high-quality materials. Additionally, the aqueous medium minimizes the need for toxic solvents, aligning with green chemistry principles. However, the method's reliance on specialized equipment and longer reaction times may pose challenges for large-scale production [69], [70], [71], [72], [73].

DIAGNOSTIC APPLICATIONS

Magnetic Resonance Imaging (MRI)

Iron oxide nanoparticles (IONPs) play a pivotal role in enhancing the capabilities of magnetic resonance imaging (MRI) as contrast agents [18], [74], [75]. These nanoparticles significantly improve the resolution and clarity of breast tissue images by amplifying signal intensity due to their superparamagnetic properties. This heightened signal enables the precise detection of tumors, even in their earliest stages, contributing to early diagnosis and improved patient outcomes [18], [19], [76].

Beyond their inherent magnetic properties, the utility of IONPs in MRI is further enhanced through surface functionalization. By conjugating IONPs with tumor-specific ligands, such as monoclonal antibodies, peptides, or small molecules, their targeting capability is vastly improved. This specificity ensures that the nanoparticles preferentially accumulate in cancerous tissues, thereby reducing background noise and enhancing contrast in the affected areas [19], [35], [37], [77].

Recent advancements have also explored multifunctional IONPs that integrate imaging with therapeutic capabilities. These theranostic agents not only provide real-time visualization of tumors but also allow simultaneous delivery of therapeutic agents. For instance, IONPs functionalized with both imaging and drug delivery moieties enable clinicians to monitor the treatment process dynamically [12], [18], [21], [78].

Moreover, the safety profile and biocompatibility of IONPs make them highly suitable for repeated imaging sessions, which is often required for monitoring disease progression or therapeutic efficacy. Overall, the incorporation of IONPs into MRI represents a paradigm shift in imaging technology, providing unparalleled accuracy, specificity, and versatility in breast cancer diagnostics [4], [18], [79], [80].

Biosensors

Iron oxide nanoparticles (IONPs) are increasingly being incorporated into advanced biosensor platforms designed for the detection of key breast cancer biomarkers, such as HER2 and CA 15-3. These biomarkers are critical for early diagnosis, monitoring disease progression, and assessing treatment efficacy [81], [82], [83], [84].

IONP-based biosensors leverage the unique magnetic and optical properties of these nanoparticles to achieve highly sensitive and specific detection. The integration of IONPs into biosensor systems enhances their performance by enabling rapid signal amplification and reducing the likelihood of false positives. Techniques such as magnetic immunoassays, where IONPs are conjugated with antibodies specific to breast cancer biomarkers, have demonstrated remarkable accuracy in identifying cancerous conditions. Moreover, the compact size and surface functionalization of IONPs facilitate their integration with microfluidic devices, paving the way for portable and point-of-care diagnostic tools. These advancements hold the potential to make breast cancer diagnostics more accessible, particularly in resource-limited settings where traditional laboratory infrastructure is unavailable [85], [86], [87], [88].

IONPs also enable multiplexed detection of multiple biomarkers simultaneously, offering a comprehensive diagnostic profile in a single test. This capability is crucial for personalized medicine, where detailed

biomarker data can guide tailored therapeutic strategies. Overall, the incorporation of IONPs into biosensor technologies represents a significant step forward in breast cancer diagnostics. By combining sensitivity, specificity, and versatility, these systems have the potential to transform early detection and monitoring, ultimately improving patient outcomes [89], [90], [91].

THERAPEUTIC APPLICATIONS

Targeted Drug Delivery

Iron oxide nanoparticles (IONPs) represent a breakthrough in achieving precision medicine through targeted drug delivery. These nanoparticles can be loaded with chemotherapeutic agents and directed to specific tumor sites using an external magnetic field. By leveraging their magnetic properties, IONPs offer a non-invasive means to enhance the localization of drugs at the tumor site, thereby minimizing systemic toxicity often associated with conventional chemotherapy. This targeted approach not only improves drug efficacy but also reduces side effects, ensuring better tolerability for patients [92], [93], [94], [95].

A prime example is the use of doxorubicin-loaded IONPs, which have shown remarkable promise in preclinical models. In these studies, the nanoparticles efficiently delivered doxorubicin directly to the tumor cells, resulting in enhanced therapeutic efficacy and reduced off-target effects [96], [97], [98]. Furthermore, functionalizing IONPs with ligands such as folic acid or monoclonal antibodies enhances their ability to recognize and bind specifically to cancer cells, further improving targeting precision [99], [100], [101], [102], [103].

Recent advancements have explored the development of stimuli-responsive IONPs that release their therapeutic payload in response to specific triggers such as pH changes, enzymes, or temperature variations within the tumor microenvironment. This smart delivery system adds another layer of control, ensuring that the drug is released only in the vicinity of the tumor, maximizing therapeutic benefits [104], [105], [106], [107].

IONP-based drug delivery systems are a cornerstone of future oncology treatments, offering a pathway to integrate therapy and diagnostics (theranostics) in a single platform, thus enabling real-time monitoring of treatment efficacy and tumor response.

Hyperthermia Therapy

Magnetic hyperthermia therapy harnesses the unique properties of iron oxide nanoparticles (IONPs) to induce localized heating in cancer cells [108], [109], [110]. When exposed to an alternating magnetic field, IONPs generate heat through Néel and Brownian relaxation processes, effectively raising the temperature in the tumor microenvironment to a therapeutic range (42-45°C). This localized heat induces apoptosis and necrosis in cancer cells, disrupting their growth and survival mechanisms, while sparing surrounding healthy tissues due to precise targeting [111], [112].

The use of IONPs in hyperthermia therapy shows great potential as a complementary treatment alongside radiotherapy and chemotherapy. The elevated temperatures can sensitize cancer cells to radiation and enhance the efficacy of chemotherapeutic agents by improving their penetration and activity. Furthermore, hyperthermia has been shown to disrupt the tumor vasculature, increasing the permeability of the tumor microenvironment and facilitating drug delivery [113], [114], [115], [116].

Functionalized IONPs with tumor-specific targeting ligands, such as antibodies or peptides, further improve the specificity and efficiency of hyperthermia therapy. Recent studies have also explored the integration of IONPs into multifunctional platforms, combining hyperthermia with imaging and drug delivery, enabling real-time monitoring and therapeutic synergy [117], [118], [119], [120].

Despite these advancements, challenges remain, including the optimization of magnetic field parameters, uniform heat distribution, and minimizing off-target effects. Ongoing research and clinical trials aim to address these hurdles, paving the way for the widespread adoption of IONP-based hyperthermia as a safe and effective modality in breast cancer treatment.

Immunotherapy Enhancement

Iron oxide nanoparticles (IONPs) hold significant promise in advancing immunotherapy for breast cancer by acting as modulators of the immune system. These nanoparticles can be engineered to deliver immunomodulatory agents, such as cytokines, antigens, or small molecules, directly to immune cells, enhancing their activation and effectiveness against tumors. By providing a controlled and targeted delivery mechanism, IONPs minimize off-target effects and improve the therapeutic index of immunomodulatory drugs [121], [122], [123], [124].

Additionally, IONPs can serve as adjuvants, enhancing the immune response to cancer vaccines. When conjugated with tumor antigens, IONPs facilitate efficient antigen presentation by dendritic cells, leading to robust activation of T cells and subsequent antitumor immunity. This property is particularly valuable in developing personalized cancer vaccines tailored to the unique antigenic profile of a patient's tumor [125], [126], [127], [128], [129].

Emerging research also highlights the potential of combining IONPs with immune checkpoint inhibitors, such as anti-PD-1 or anti-CTLA-4 antibodies. This combination strategy has shown promise in overcoming immune evasion mechanisms employed by cancer cells. By simultaneously enhancing immune activation and disrupting tumor-induced immunosuppression, the synergy between IONPs and checkpoint inhibitors could lead to improved treatment outcomes [130], [131], [132]. Moreover, the theranostic capabilities of IONPs enable real-time monitoring of immune responses and therapeutic efficacy through imaging modalities such as MRI. This integration of diagnostics and therapy allows for dynamic adjustments to treatment strategies, aligning with the principles of precision medicine [133], [134], [135], [136], [137].

IONPs are paving the way for innovative approaches in cancer immunotherapy, offering a platform to enhance antitumor immunity, improve therapeutic outcomes, and integrate diagnostics with treatment.

CHALLENGES AND FUTURE DIRECTIONS

Despite their transformative potential, the clinical translation of iron oxide nanoparticles (IONPs) is fraught with several challenges that need to be systematically addressed. One major obstacle is the scalability of production, as maintaining consistency in nanoparticle size, shape, and functionalization on a large scale remains technically demanding [138], [139], [140]. Ensuring long-term biocompatibility is another critical concern, as the potential for unintended interactions, toxicity, and clearance pathways must be rigorously evaluated in vivo to gain regulatory approval [141], [142], [143].

Regulatory challenges also pose significant barriers, given the stringent requirements for demonstrating safety, efficacy, and reproducibility in nanoparticle-based therapies [144], [145]. Harmonizing standards for the production and clinical use of IONPs across international regulatory bodies is essential to streamline their path to market [146], [147], [148], [149].

To overcome these hurdles, research is focusing on advanced synthesis techniques, such as green chemistry approaches that are environmentally friendly and cost-effective, and methods that enhance nanoparticle stability and uniformity [150], [151], [152]. Rigorous preclinical testing, including long-term studies on biodistribution and clearance, is crucial for addressing safety concerns [153], [154], [155]. Furthermore, fostering collaborations between

academia, industry, and regulatory agencies can accelerate innovation and facilitate the translation of laboratory findings into clinical applications [156], [157], [158], [159].

Future directions in the field include the development of multifunctional IONPs that integrate diagnostic and therapeutic capabilities, enabling a theranostic approach to cancer care [160], [161], [162]. The integration of artificial intelligence and machine learning can also enhance the design of personalized IONP-based treatments, optimizing their efficacy and reducing potential side effects [163], [164]. Additionally, exploring combination therapies that synergize IONPs with existing treatments, such as immunotherapy and radiotherapy, could unlock new frontiers in precision oncology. These advancements promise to bring the transformative potential of IONPs closer to clinical reality, offering hope for improved breast cancer outcomes [165], [166], [167], [168], [169].

CONCLUSION

Iron oxide nanoparticles (IONPs) are at the forefront of innovation in breast cancer care, addressing critical challenges in both diagnosis and treatment. Their unique properties, such as superparamagnetism, biocompatibility, and functionalization flexibility, empower them to enhance imaging precision, enable targeted drug delivery, and introduce novel therapeutic strategies like hyperthermia and immunotherapy enhancement. These capabilities underscore their potential to transform traditional approaches to cancer management.

Preclinical studies have consistently demonstrated the efficacy and safety of IONPs, highlighting their ability to improve specificity and reduce systemic side effects compared to conventional methods. Moreover, advancements in theranostics, which combine therapeutic and diagnostic functions into a single platform, exemplify the paradigm shift that IONPs can bring to personalized medicine.

However, the journey from the laboratory to clinical practice requires addressing challenges such as large-scale synthesis, long-term biocompatibility, and regulatory hurdles. Collaborative efforts among researchers, industry stakeholders, and regulatory bodies will be essential in overcoming these obstacles.

Looking ahead, the integration of artificial intelligence and machine learning offers exciting opportunities to optimize the design and application of IONPs, paving the way for highly personalized and effective treatment regimens. Furthermore, the exploration of IONPs in combination therapies, particularly with immunotherapy and radiotherapy, holds immense potential for achieving synergistic effects that enhance therapeutic outcomes.

In conclusion, the versatile and multifunctional nature of IONPs represents a promising avenue for revolutionizing breast cancer care. Continued research, innovation, and collaborative efforts are pivotal in translating these breakthroughs into clinical reality, ultimately improving survival rates and quality of life for patients worldwide.

ACKNOWLEDGEMENT

The author is grateful to his Ph.D. guide Prof. Syed Sirajul Islam, former Professor, Department of Chemistry and Chemical Technology, Vidyasagar University, West Bengal, for his continuous encouragement and constructive suggestions. The author is also grateful to his Institute for providing necessary research facilities.

CONFLICT OF INTEREST

The author declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

REFERENCES

[1]. A. Ahmad, "Breast Cancer Statistics: Recent Trends," in Breast Cancer Metastasis and Drug Resistance, vol. 1152, A. Ahmad, Ed., in Advances in Experimental Medicine and Biology, vol. 1152. , Cham: Springer International Publishing, 2019, pp. 1–7. doi: 10.1007/978-3-030-20301-6_1.

[2]. M. Arnold et al., "Current and future burden of breast cancer: Global statistics for 2020 and 2040," The Breast, vol. 66, pp. 15–23, Dec. 2022, doi: 10.1016/j.breast.2022.08.010.

[3]. L. Wilkinson and T. Gathani, "Understanding breast cancer as a global health concern," Br. J. Radiol., vol. 95, no. 1130, p. 20211033, Feb. 2022, doi: 10.1259/bjr.20211033.

[4]. X. Yan, S. Li, H. Yan, C. Yu, and F. Liu, "IONPs-Based Medical Imaging in Cancer Care: Moving Beyond Traditional Diagnosis and Therapeutic Assessment," Int. J. Nanomedicine, vol. Volume 18, pp. 1741–1763, Apr. 2023, doi: 10.2147/IJN.S399047.

[5]. S. N. Aleksakhina, A. Kashyap, and E. N. Imyanitov, "Mechanisms of acquired tumor drug resistance," Biochim. Biophys. Acta BBA - Rev. Cancer, vol. 1872, no. 2, p. 188310, Dec. 2019, doi: 10.1016/j.bbcan.2019.188310.

[6]. S. Crucitta et al., "Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours," Cancer Treat. Rev., vol. 104, p. 102340, Mar. 2022, doi: 10.1016/j.ctrv.2022.102340.

[7]. G. Gu, D. Dustin, and S. A. Fuqua, "Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment," Curr. Opin. Pharmacol., vol. 31, pp. 97–103, Dec. 2016, doi: 10.1016/j.coph.2016.11.005.

[8]. M. Labrie, J. S. Brugge, G. B. Mills, and I. K. Zervantonakis, "Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer," Nat. Rev. Cancer, vol. 22, no. 6, pp. 323–339, Jun. 2022, doi: 10.1038/s41568-022-00454-5.

[9]. Z.-F. Lim and P. C. Ma, "Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy," J. Hematol. Oncol.J Hematol Oncol, vol. 12, no. 1, p. 134, Dec. 2019, doi: 10.1186/s13045-019-0818-2.

[10]. T. Saha and K. E. Lukong, "Breast Cancer Stem-Like Cells in Drug Resistance: A Review of Mechanisms and Novel Therapeutic Strategies to Overcome Drug Resistance," Front. Oncol., vol. 12, p. 856974, Mar. 2022, doi: 10.3389/fonc.2022.856974.

[11]. N. Ajinkya, X. Yu, P. Kaithal, H. Luo, P. Somani, and S. Ramakrishna, "Magnetic Iron Oxide Nanoparticle (IONP) Synthesis to Applications: Present and Future," Materials, vol. 13, no. 20, p. 4644, Oct. 2020, doi: 10.3390/ma13204644.

[12]. E. Aram et al., "Smart and Multi-Functional Magnetic Nanoparticles for Cancer Treatment Applications: Clinical Challenges and Future Prospects," Nanomaterials, vol. 12, no. 20, p. 3567, Oct. 2022, doi: 10.3390/nano12203567.

[13]. P. R. S. Baabu, H. K. Kumar, M. B. Gumpu, J. Babu K, A. J. Kulandaisamy, and J. B. B. Rayappan, "Iron Oxide Nanoparticles: A Review on the Province of Its Compounds, Properties and Biological Applications," Materials, vol. 16, no. 1, p. 59, Dec. 2022, doi: 10.3390/ma16010059.

[14]. R. S. Chouhan, M. Horvat, J. Ahmed, N. Alhokbany, S. M. Alshehri, and S. Gandhi, "Magnetic Nanoparticles—A Multifunctional Potential Agent for Diagnosis and Therapy," Cancers, vol. 13, no. 9, p. 2213, May 2021, doi: 10.3390/cancers13092213.

[15]. M. Salehirozveh, P. Dehghani, and I. Mijakovic, "Synthesis, Functionalization, and Biomedical

Applications of Iron Oxide Nanoparticles (IONPs)," J. Funct. Biomater., vol. 15, no. 11, p. 340, Nov. 2024, doi: 10.3390/jfb15110340.

[16]. P. Farinha, J. M. P. Coelho, C. P. Reis, and M. M. Gaspar, "A Comprehensive Updated Review on Magnetic Nanoparticles in Diagnostics," Nanomaterials, vol. 11, no. 12, p. 3432, Dec. 2021, doi: 10.3390/nano11123432.

[17]. C. Han et al., "Multifunctional iron oxide-carbon hybrid nanoparticles for targeted fluorescent/MR dual-modal imaging and detection of breast cancer cells," Anal. Chim. Acta, vol. 1067, pp. 115–128, Aug. 2019, doi: 10.1016/j.aca.2019.03.054.

[18]. M. Rahman, "Magnetic Resonance Imaging and Iron-oxide Nanoparticles in the era of Personalized Medicine," Nanotheranostics, vol. 7, no. 4, pp. 424–449, 2023, doi: 10.7150/ntno.86467.

[19]. L. Wu, C. Wang, and Y. Li, "Iron Oxide Nanoparticle Targeting Mechanism and its Application in Tumor Magnetic Resonance Imaging and Therapy," Nanomed., vol. 17, no. 21, pp. 1567–1583, Sep. 2022, doi: 10.2217/nnm-2022-0246.

[20]. E. Alphandéry, "Iron oxide nanoparticles for therapeutic applications," Drug Discov. Today, vol. 25, no. 1, pp. 141–149, Jan. 2020, doi: 10.1016/j.drudis.2019.09.020.

[21]. A. N. Al-Thani, A. G. Jan, M. Abbas, M. Geetha, and K. K. Sadasivuni, "Nanoparticles in cancer theragnostic and drug delivery: A comprehensive review," Life Sci., vol. 352, p. 122899, Sep. 2024, doi: 10.1016/j.lfs.2024.122899.

[22]. V. Sachdeva, A. Monga, R. Vashisht, D. Singh, A. Singh, and N. Bedi, "Iron Oxide Nanoparticles: The precise strategy for targeted delivery of genes, oligonucleotides and peptides in cancer therapy," J. Drug Deliv. Sci. Technol., vol. 74, p. 103585, Aug. 2022, doi: 10.1016/j.jddst.2022.103585.

[23]. M. Saeed, W. Ren, and A. Wu, "Therapeutic applications of iron oxide based nanoparticles in cancer: basic concepts and recent advances," Biomater. Sci., vol. 6, no. 4, pp. 708–725, 2018, doi: 10.1039/C7BM00999B.

[24]. H. Etemadi and P. G. Plieger, "Magnetic Fluid Hyperthermia Based on Magnetic Nanoparticles: Physical Characteristics, Historical Perspective, Clinical Trials, Technological Challenges, and Recent Advances," Adv. Ther., vol. 3, no. 11, p. 2000061, Nov. 2020, doi: 10.1002/adtp.202000061.

[25]. H. Gavilán et al., "Magnetic nanoparticles and clusters for magnetic hyperthermia: optimizing their heat performance and developing combinatorial therapies to tackle cancer," Chem. Soc. Rev., vol. 50, no. 20, pp. 11614–11667, 2021, doi: 10.1039/D1CS00427A.

[26]. S. K. Sharma, N. Shrivastava, F. Rossi, L. D. Tung, and N. T. K. Thanh, "Nanoparticles-based magnetic and photo induced hyperthermia for cancer treatment," Nano Today, vol. 29, p. 100795, Dec. 2019, doi: 10.1016/j.nantod.2019.100795.

[27]. A. T. Shivanna, B. S. Dash, and J.-P. Chen, "Functionalized Magnetic Nanoparticles for Alternating Magnetic Field- or Near Infrared Light-Induced Cancer Therapies," Micromachines, vol. 13, no. 8, p. 1279, Aug. 2022, doi: 10.3390/mi13081279.

[28]. B. Govindan, M. A. Sabri, A. Hai, F. Banat, and M. A. Haija, "A Review of Advanced Multifunctional Magnetic Nanostructures for Cancer Diagnosis and Therapy Integrated into an Artificial Intelligence Approach," Pharmaceutics, vol. 15, no. 3, p. 868, Mar. 2023, doi: 10.3390/pharmaceutics15030868.

[29]. O. Ouled Ltaief et al., "Recent developments in cancer diagnosis and treatment using nanotechnology," Ann. Med. Surg., vol. 86, no. 8, pp. 4541–4554, Aug. 2024, doi: 10.1097/MS9.0000000000002271.

[30]. A. Nehe and A. Kulkarni, "Fundamentals of Superparamagnetic Iron Oxide Nanoparticles: Recent Update," J. Microsc. Ultrastruct., vol. 0, no. 0, p. 0, 2023, doi: 10.4103/jmau.jmau_17_22.

[31]. M.-N. Savari and A. Jabali, "Properties of Iron Oxide Nanoparticles (IONPs)," in Theranostic Iron-Oxide Based Nanoplatforms in Oncology, in Nanomedicine and Nanotoxicology. , Singapore: Springer Nature Singapore, 2023, pp. 49–65. doi: 10.1007/978-981-99-6507-6_4.

[32]. H. Ghazal et al., "Role of nanoparticles in enhancing chemotherapy efficacy for cancer treatment," Mater., vol. 2, p. 100128, Jan. 2024, doi: 10.1016/j.nxmate.2024.100128.

[33]. M. I. Khan et al., "Recent Progress in Nanostructured Smart Drug Delivery Systems for Cancer Therapy: A Review," ACS Appl. Bio Mater., vol. 5, no. 3, pp. 971–1012, Mar. 2022, doi: 10.1021/acsabm.2c00002.

[34]. J. B. Oehler, W. Rajapaksha, and H. Albrecht, "Emerging Applications of Nanoparticles in the Diagnosis and Treatment of Breast Cancer," J. Pers. Med., vol. 14, no. 7, p. 723, Jul. 2024, doi: 10.3390/jpm14070723.

[35]. L. Sun et al., "Smart nanoparticles for cancer therapy," Signal Transduct. Target. Ther., vol. 8, no. 1, p. 418, Nov. 2023, doi: 10.1038/s41392-023-01642-x.

[36]. R. Al-Shalabi, R. Abu-Huwaij, R. Hamed, and M. M. Abbas, "The antimicrobial and the antiproliferative effect of human triple negative breast cancer cells using the greenly synthesized iron oxide nanoparticles," J. Drug Deliv. Sci. Technol., vol. 75, p. 103642, Sep. 2022, doi: 10.1016/j.jddst.2022.103642.

[37]. J. Halder et al., "Trends in iron oxide nanoparticles: a nano-platform for theranostic application in breast cancer," J. Drug Target., pp. 1–21, Jul. 2022, doi: 10.1080/1061186X.2022.2095389.

[38]. Md. S. Shakil, Md. A. Hasan, and S. R. Sarker, "Iron Oxide Nanoparticles for Breast Cancer Theranostics," Curr. Drug Metab., vol. 20, no. 6, pp. 446–456, Jul. 2019, doi: 10.2174/1389200220666181122105043.

[39]. S. Thoidingjam and A. B. Tiku, "New developments in breast cancer therapy: role of iron oxide nanoparticles," Adv. Nat. Sci. Nanosci. Nanotechnol., vol. 8, no. 2, p. 023002, Jun. 2017, doi: 10.1088/2043-6254/aa5e33.

[40]. H. Hosseinkazemi et al., "Applications of Iron Oxide Nanoparticles against Breast Cancer," J. Nanomater., vol. 2022, no. 1, p. 6493458, Jan. 2022, doi: 10.1155/2022/6493458.

[41]. M. Xie et al., "Surface Engineering of Magnetic Iron Oxide Nanoparticles for Breast Cancer Diagnostics and Drug Delivery," Int. J. Nanomedicine, vol. Volume 19, pp. 8437–8461, Aug. 2024, doi: 10.2147/IJN.S477652.

[42]. J. Zhang, T. Zhang, and J. Gao, "Biocompatible Iron Oxide Nanoparticles for Targeted Cancer Gene Therapy: A Review," Nanomaterials, vol. 12, no. 19, p. 3323, Sep. 2022, doi: 10.3390/nano12193323.

[43]. S. Ghosh et al., "Diosgenin Functionalized Iron Oxide Nanoparticles as Novel Nanomaterial Against Breast Cancer," J. Nanosci. Nanotechnol., vol. 15, no. 12, pp. 9464–9472, Dec. 2015, doi: 10.1166/jnn.2015.11704.

[44]. M. Salehirozveh, P. Dehghani, and I. Mijakovic, "Synthesis, Functionalization, and Biomedical Applications of Iron Oxide Nanoparticles (IONPs)," J. Funct. Biomater., vol. 15, no. 11, p. 340, Nov. 2024, doi: 10.3390/jfb15110340.

[45]. W. Xie et al., "Shape-, size- and structure-controlled synthesis and biocompatibility of

iron oxide nanoparticles for magnetic theranostics," Theranostics, vol. 8, no. 12, pp. 3284–3307, 2018, doi: 10.7150/thno.25220.

[46]. L. Zhu, Z. Zhou, H. Mao, and L. Yang, "Magnetic Nanoparticles for Precision Oncology: Theranostic Magnetic Iron Oxide Nanoparticles for Image-Guided and Targeted Cancer Therapy," Nanomed., vol. 12, no. 1, pp. 73–87, Jan. 2017, doi: 10.2217/nnm-2016-0316.

[47]. H. Arami, A. Khandhar, D. Liggitt, and K. M. Krishnan, "In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles," Chem. Soc. Rev., vol. 44, no. 23, pp. 8576–8607, 2015, doi: 10.1039/C5CS00541H.

[48]. L. S. Ganapathe, M. A. Mohamed, R. Mohamad Yunus, and D. D. Berhanuddin, "Magnetite (Fe3O4) Nanoparticles in Biomedical Application: From Synthesis to Surface Functionalisation," Magnetochemistry, vol. 6, no. 4, p. 68, Dec. 2020, doi: 10.3390/magnetochemistry6040068.

[49]. L. H. Reddy, J. L. Arias, J. Nicolas, and P. Couvreur, "Magnetic Nanoparticles: Design and Characterization, Toxicity and Biocompatibility, Pharmaceutical and Biomedical Applications," Chem. Rev., vol. 112, no. 11, pp. 5818–5878, Nov. 2012, doi: 10.1021/cr300068p.

[50]. B. Rezaei et al., "Effect of Polymer and Cell Membrane Coatings on Theranostic Applications of Nanoparticles: A Review," Adv. Healthc. Mater., p. 2401213, Jun. 2024, doi: 10.1002/adhm.202401213.

[51]. V. V. Chrishtop, V. A. Mironov, A. Y. Prilepskii, V. G. Nikonorova, and V. V. Vinogradov, "Organ-specific toxicity of magnetic iron oxide-based nanoparticles," Nanotoxicology, vol. 15, no. 2, pp. 167–204, Feb. 2021, doi: 10.1080/17435390.2020.1842934.

[52]. U. S. Ezealigo, B. N. Ezealigo, S. O. Aisida, and F. I. Ezema, "Iron oxide nanoparticles in biological systems: Antibacterial and toxicology perspective," JCIS Open, vol. 4, p. 100027, Dec. 2021, doi: 10.1016/j.jciso.2021.100027.

[53]. A. Shah and M. A. Dobrovolskaia, "Immunological effects of iron oxide nanoparticles and iron-based complex drug formulations: Therapeutic benefits, toxicity, mechanistic insights, and translational considerations," Nanomedicine Nanotechnol. Biol. Med., vol. 14, no. 3, pp. 977–990, Apr. 2018, doi: 10.1016/j.nano.2018.01.014.

[54]. J. Estelrich and M. A. Busquets, "Iron Oxide Nanoparticles in Photothermal Therapy," Molecules, vol. 23, no. 7, p. 1567, Jun. 2018, doi: 10.3390/molecules23071567.

[55]. N. Lamichhane, S. Sharma, Parul, A. Verma, I. Roy, and T. Sen, "Iron Oxide-Based Magneto-Optical Nanocomposites for In Vivo Biomedical Applications," Biomedicines, vol. 9, no. 3, p. 288, Mar. 2021, doi: 10.3390/biomedicines9030288.

[56]. A. G. Roca et al., "Iron oxide nanoparticles (Fe3O4, γ -Fe2O3 and FeO) as photothermal heat mediators in the first, second and third biological windows," Phys. Rep., vol. 1043, pp. 1–35, Dec. 2023, doi: 10.1016/j.physrep.2023.10.003.

[57]. F. Khan, M. N. Karimi, and O. Khan, "Exploring the scalability and commercial viability of biosynthesized nanoparticles for cooling panels with the help of Artificial Intelligence and solar energy systems," Green Technol. Sustain., vol. 1, no. 3, p. 100036, Sep. 2023, doi: 10.1016/j.grets.2023.100036.

[58]. P. Kumar et al., "Catalyzing innovation: Exploring iron oxide nanoparticles - Origins, advancements, and future application horizons," Coord. Chem. Rev., vol. 507, p.

215750, May 2024, doi: 10.1016/j.ccr.2024.215750.

[59]. A. G. Leonel, A. A. P. Mansur, and H. S. Mansur, "Advanced Functional Nanostructures based on Magnetic Iron Oxide Nanomaterials for Water Remediation: A Review," Water Res., vol. 190, p. 116693, Feb. 2021, doi: 10.1016/j.watres.2020.116693.

[60]. M. O. Besenhard et al., "Co-precipitation synthesis of stable iron oxide nanoparticles with NaOH: New insights and continuous production via flow chemistry," Chem. Eng. J., vol. 399, p. 125740, Nov. 2020, doi: 10.1016/j.cej.2020.125740.

[61]. M. Farahmandjou and F. Soflaee, "Synthesis and Characterization of α-Fe2O3 Nanoparticles by Simple Co-Precipitation Method," Phys. Chem. Res., vol. 3, no. 3, Sep. 2015, doi: 10.22036/pcr.2015.9193.

[62]. A. P. LaGrow et al., "Unravelling the growth mechanism of the co-precipitation of iron oxide nanoparticles with the aid of synchrotron X-Ray diffraction in solution," Nanoscale, vol. 11, no. 14, pp. 6620–6628, 2019, doi: 10.1039/C9NR00531E.

[63]. S. Riaz, M. Bashir, and S. Naseem, "Iron Oxide Nanoparticles Prepared by Modified Co-Precipitation Method," IEEE Trans. Magn., vol. 50, no. 1, pp. 1–4, Jan. 2014, doi: 10.1109/TMAG.2013.2277614.

[64]. V. Fokina, M. Wilke, M. Dulle, S. Ehlert, and S. Förster, "Size Control of Iron Oxide Nanoparticles Synthesized by Thermal Decomposition Methods," J. Phys. Chem. C, vol. 126, no. 50, pp. 21356–21367, Dec. 2022, doi: 10.1021/acs.jpcc.2c05380.

[65]. W. Glasgow et al., "Continuous synthesis of iron oxide (Fe3O4) nanoparticles via thermal decomposition," Particuology, vol. 26, pp. 47–53, Jun. 2016, doi: 10.1016/j.partic.2015.09.011.

[66]. L. Gonzalez-Moragas, S.-M. Yu, N. Murillo-Cremaes, A. Laromaine, and A. Roig, "Scale-up synthesis of iron oxide nanoparticles by microwave-assisted thermal decomposition," Chem. Eng. J., vol. 281, pp. 87–95, Dec. 2015, doi: 10.1016/j.cej.2015.06.066.

[67]. R. Hufschmid et al., "Synthesis of phase-pure and monodisperse iron oxide nanoparticles by thermal decomposition," Nanoscale, vol. 7, no. 25, pp. 11142–11154, 2015, doi: 10.1039/C5NR01651G.

[68]. M. Unni et al., "Thermal Decomposition Synthesis of Iron Oxide Nanoparticles with Diminished Magnetic Dead Layer by Controlled Addition of Oxygen," ACS Nano, vol. 11, no. 2, pp. 2284–2303, Feb. 2017, doi: 10.1021/acsnano.7b00609.

[69]. T. Adschiri, Y. Hakuta, K. Sue, and K. Arai, "Hydrothermal Synthesis of Metal Oxide Nanoparticles at Supercritical Conditions," J. Nanoparticle Res., vol. 3, no. 2/3, pp. 227–235, 2001, doi: 10.1023/A:1017541705569.

[70]. S. Ge et al., "Facile Hydrothermal Synthesis of Iron Oxide Nanoparticles with Tunable Magnetic Properties," J. Phys. Chem. C, vol. 113, no. 31, pp. 13593–13599, Aug. 2009, doi: 10.1021/jp902953t.

[71]. F. Ozel, H. Kockar, and O. Karaagac, "Growth of Iron Oxide Nanoparticles by Hydrothermal Process: Effect of Reaction Parameters on the Nanoparticle Size," J. Supercond. Nov. Magn., vol. 28, no. 3, pp. 823–829, Mar. 2015, doi: 10.1007/s10948-014-2707-9.

[72]. S. Takami, T. Sato, T. Mousavand, S. Ohara, M. Umetsu, and T. Adschiri, "Hydrothermal synthesis of surface-modified iron oxide nanoparticles," Mater. Lett., vol. 61, no. 26, pp. 4769–4772, Oct. 2007, doi: 10.1016/j.matlet.2007.03.024.

[73]. C. Xu and A. S. Teja, "Continuous hydrothermal synthesis of iron oxide and PVA-

protected iron oxide nanoparticles," J. Supercrit. Fluids, vol. 44, no. 1, pp. 85–91, Feb. 2008, doi: 10.1016/j.supflu.2007.09.033.

[74]. I. Fernández-Barahona, M. Muñoz-Hernando, J. Ruiz-Cabello, F. Herranz, and J. Pellico, "Iron Oxide Nanoparticles: An Alternative for Positive Contrast in Magnetic Resonance Imaging," Inorganics, vol. 8, no. 4, p. 28, Apr. 2020, doi: 10.3390/inorganics8040028.

[75]. M. Jeon, M. V. Halbert, Z. R. Stephen, and M. Zhang, "Iron Oxide Nanoparticles as T1 Contrast Agents for Magnetic Resonance Imaging: Fundamentals, Challenges, Applications, and Prospectives," Adv. Mater., vol. 33, no. 23, p. 1906539, Jun. 2021, doi: 10.1002/adma.201906539.

[76]. A. Avasthi, C. Caro, E. Pozo‐Torres, M. P. Leal, and M. L. García‐Martín, "Magnetic Nanoparticles as MRI Contrast Agents," in Surface-modified Nanobiomaterials for Electrochemical and Biomedicine Applications, A. R. Puente-Santiago and D. Rodríguez-Padrón, Eds., in Topics in Current Chemistry Collections. , Cham: Springer International Publishing, 2020, pp. 49–91. doi: 10.1007/978-3-030-55502-3_3.

[77]. D. Zhi, T. Yang, J. Yang, S. Fu, and S. Zhang, "Targeting strategies for superparamagnetic iron oxide nanoparticles in cancer therapy," Acta Biomater., vol. 102, pp. 13–34, Jan. 2020, doi: 10.1016/j.actbio.2019.11.027.

[78]. A. L. Cortajarena et al., "Engineering Iron Oxide Nanoparticles for Clinical Settings," Nanobiomedicine, vol. 1, p. 2, Jan. 2014, doi: 10.5772/58841.

[79]. M. Abdelmonem, E. L. Albert, N. K. R. Zainon, E. Z. Tarmizie, S. H. Zyoud, and C. A. C. Abdullah, "Biosynthesis of Iron Oxide Nanoparticles (IONPs): Toxicity Evaluation and Applications for Magnetic Resonance Imaging and Magnetic Hyperthermia," in Emerging Applications of Novel Nanoparticles, vol. 37, S. Anil Bansal, V. Khanna, N. Balakrishnan, and P. Gupta, Eds., in Lecture Notes in Nanoscale Science and Technology, vol. 37. , Cham: Springer Nature Switzerland, 2024, pp. 229–249. doi: 10.1007/978-3-031-57843-4_9.

[80]. A. N. Al-Thani, A. G. Jan, M. Abbas, M. Geetha, and K. K. Sadasivuni, "Nanoparticles in cancer theragnostic and drug delivery: A comprehensive review," Life Sci., vol. 352, p. 122899, Sep. 2024, doi: 10.1016/j.lfs.2024.122899.

[81]. J. Halder et al., "Trends in iron oxide nanoparticles: a nano-platform for theranostic application in breast cancer," J. Drug Target., pp. 1–21, Jul. 2022, doi: 10.1080/1061186X.2022.2095389.

[82]. M. Sharifi, A. Hasan, F. Attar, A. Taghizadeh, and M. Falahati, "Development of point-of-care nanobiosensors for breast cancers diagnosis," Talanta, vol. 217, p. 121091, Sep. 2020, doi: 10.1016/j.talanta.2020.121091.

[83]. L. Sitia et al., "HER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment," Cancers, vol. 14, no. 10, p. 2424, May 2022, doi: 10.3390/cancers14102424.

[84]. M. A. Subhan, "Advances with metal oxide-based nanoparticles as MDR metastatic breast cancer therapeutics and diagnostics," RSC Adv., vol. 12, no. 51, pp. 32956–32978, 2022, doi: 10.1039/D2RA02005J.

[85]. R. S. Chouhan, M. Horvat, J. Ahmed, N. Alhokbany, S. M. Alshehri, and S. Gandhi, "Magnetic Nanoparticles—A Multifunctional Potential Agent for Diagnosis and Therapy," Cancers, vol. 13, no. 9, p. 2213, May 2021, doi: 10.3390/cancers13092213.

[86]. M. Kumar, P. Kumar, S. Sagar, and A. Chaudhary, "Iron oxide nanoparticles approaching to eradicate her2-positive breast cancer: A review," Int. J. Health Sci., pp.

12680–12707, Jun. 2022, doi: 10.53730/ijhs.v6nS2.8308.

[87]. L. Sitia et al., "HER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment," Cancers, vol. 14, no. 10, p. 2424, May 2022, doi: 10.3390/cancers14102424.

[88]. M. A. Subhan, "Advances with metal oxide-based nanoparticles as MDR metastatic breast cancer therapeutics and diagnostics," RSC Adv., vol. 12, no. 51, pp. 32956–32978, 2022, doi: 10.1039/D2RA02005J.

[89]. P. Farinha, J. M. P. Coelho, C. P. Reis, and M. M. Gaspar, "A Comprehensive Updated Review on Magnetic Nanoparticles in Diagnostics," Nanomaterials, vol. 11, no. 12, p. 3432, Dec. 2021, doi: 10.3390/nano11123432.

[90]. B. Govindan, M. A. Sabri, A. Hai, F. Banat, and M. A. Haija, "A Review of Advanced Multifunctional Magnetic Nanostructures for Cancer Diagnosis and Therapy Integrated into an Artificial Intelligence Approach," Pharmaceutics, vol. 15, no. 3, p. 868, Mar. 2023, doi: 10.3390/pharmaceutics15030868.

[91]. M. A. Subhan, "Advances with metal oxide-based nanoparticles as MDR metastatic breast cancer therapeutics and diagnostics," RSC Adv., vol. 12, no. 51, pp. 32956–32978, 2022, doi: 10.1039/D2RA02005J.

[92]. J. Halder et al., "Trends in iron oxide nanoparticles: a nano-platform for theranostic application in breast cancer," J. Drug Target., pp. 1–21, Jul. 2022, doi: 10.1080/1061186X.2022.2095389.

[93]. M. Saeed, W. Ren, and A. Wu, "Therapeutic applications of iron oxide based nanoparticles in cancer: basic concepts and recent advances," Biomater. Sci., vol. 6, no. 4, pp. 708–725, 2018, doi: 10.1039/C7BM00999B.

[94]. Md. S. Shakil, Md. A. Hasan, and S. R. Sarker, "Iron Oxide Nanoparticles for Breast Cancer Theranostics," Curr. Drug Metab., vol. 20, no. 6, pp. 446–456, Jul. 2019, doi: 10.2174/1389200220666181122105043.

[95]. M. A. Subhan, "Advances with metal oxide-based nanoparticles as MDR metastatic breast cancer therapeutics and diagnostics," RSC Adv., vol. 12, no. 51, pp. 32956–32978, 2022, doi: 10.1039/D2RA02005J.

[96]. H. Hosseinkazemi et al., "Applications of Iron Oxide Nanoparticles against Breast Cancer," J. Nanomater., vol. 2022, no. 1, p. 6493458, Jan. 2022, doi: 10.1155/2022/6493458.

[97]. I. I. Lungu et al., "Doxorubicin-Conjugated Iron Oxide Nanoparticles Synthesized by Laser Pyrolysis: In Vitro Study on Human Breast Cancer Cells," Polymers, vol. 12, no. 12, p. 2799, Nov. 2020, doi: 10.3390/polym12122799.

[98]. M. Norouzi, V. Yathindranath, J. A. Thliveris, B. M. Kopec, T. J. Siahaan, and D. W. Miller, "Doxorubicin-loaded iron oxide nanoparticles for glioblastoma therapy: a combinational approach for enhanced delivery of nanoparticles," Sci. Rep., vol. 10, no. 1, p. 11292, Jul. 2020, doi: 10.1038/s41598-020-68017-y.

[99]. K. Griswold et al., "Antibody-mediated targeting of iron oxide nanoparticles to the folate receptor alpha increases tumor cell association in vitro and in vivo," Int. J. Nanomedicine, p. 2595, Apr. 2015, doi: 10.2147/IJN.S79367.

[100]. S. Rajkumar and M. Prabaharan, "Multi-functional nanocarriers based on iron oxide nanoparticles conjugated with doxorubicin, poly(ethylene glycol) and folic acid as theranostics for cancer therapy," Colloids Surf. B Biointerfaces, vol. 170, pp. 529–537, Oct. 2018, doi: 10.1016/j.colsurfb.2018.06.051.

[101]. Md. S. Shakil, Md. A. Hasan, and S. R. Sarker, "Iron Oxide Nanoparticles for Breast Cancer Theranostics," Curr. Drug Metab., vol. 20, no. 6,

pp. 446–456, Jul. 2019, doi: 10.2174/1389200220666181122105043.

[102]. M. A. Subhan, "Advances with metal oxide-based nanoparticles as MDR metastatic breast cancer therapeutics and diagnostics," RSC Adv., vol. 12, no. 51, pp. 32956–32978, 2022, doi: 10.1039/D2RA02005J.

[103]. S. Thoidingjam and A. B. Tiku, "New developments in breast cancer therapy: role of iron oxide nanoparticles," Adv. Nat. Sci. Nanosci. Nanotechnol., vol. 8, no. 2, p. 023002, Jun. 2017, doi: 10.1088/2043-6254/aa5e33.

[104]. M. E. Lorkowski, P. U. Atukorale, K. B. Ghaghada, and E. Karathanasis, "Stimuli-Responsive Iron Oxide Nanotheranostics: A Versatile and Powerful Approach for Cancer Therapy," Adv. Healthc. Mater., vol. 10, no. 5, p. 2001044, Mar. 2021, doi: 10.1002/adhm.202001044.

[105]. M. A. Subhan, "Advances with metal oxide-based nanoparticles as MDR metastatic breast cancer therapeutics and diagnostics," RSC Adv., vol. 12, no. 51, pp. 32956–32978, 2022, doi: 10.1039/D2RA02005J.

[106]. L. Sun et al., "Smart nanoparticles for cancer therapy," Signal Transduct. Target. Ther., vol. 8, no. 1, p. 418, Nov. 2023, doi: 10.1038/s41392-023-01642-x.

[107]. S. Thoidingjam and A. B. Tiku, "New developments in breast cancer therapy: role of iron oxide nanoparticles," Adv. Nat. Sci. Nanosci. Nanotechnol., vol. 8, no. 2, p. 023002, Jun. 2017, doi: 10.1088/2043-6254/aa5e33.

[108]. M. E. Lorkowski, P. U. Atukorale, K. B. Ghaghada, and E. Karathanasis, "Stimuli-Responsive Iron Oxide Nanotheranostics: A Versatile and Powerful Approach for Cancer Therapy," Adv. Healthc. Mater., vol. 10, no. 5, p. 2001044, Mar. 2021, doi: 10.1002/adhm.202001044.

[109]. S. Patri, N. T. K. Thanh, and N. Kamaly, "Magnetic iron oxide nanogels for combined hyperthermia and drug delivery for cancer treatment," Nanoscale, vol. 16, no. 33, pp. 15446–15464, 2024, doi: 10.1039/D4NR02058H.

[110]. M. V. Shestovskaya, A. L. Luss, O. A. Bezborodova, V. V. Makarov, and A. A. Keskinov, "Iron Oxide Nanoparticles in Cancer Treatment: Cell Responses and the Potency to Improve Radiosensitivity," Pharmaceutics, vol. 15, no. 10, p. 2406, Sep. 2023, doi: 10.3390/pharmaceutics15102406.

[111]. H. Hosseinkazemi et al., "Applications of Iron Oxide Nanoparticles against Breast Cancer," J. Nanomater., vol. 2022, no. 1, p. 6493458, Jan. 2022, doi: 10.1155/2022/6493458.

[112]. M. Salimi, S. Sarkar, R. Saber, H. Delavari, A. M. Alizadeh, and H. T. Mulder, "Magnetic hyperthermia of breast cancer cells and MRI relaxometry with dendrimer-coated iron-oxide nanoparticles," Cancer Nanotechnol., vol. 9, no. 1, p. 7, Dec. 2018, doi: 10.1186/s12645-018-0042-8.

[113]. C. Pucci, A. Degl'Innocenti, M. Belenli Gümüş, and G. Ciofani, "Superparamagnetic iron oxide nanoparticles for magnetic hyperthermia: recent advancements, molecular effects, and future directions in the omics era," Biomater. Sci., vol. 10, no. 9, pp. 2103–2121, 2022, doi: 10.1039/D1BM01963E.

[114]. Md. S. Shakil, Md. A. Hasan, and S. R. Sarker, "Iron Oxide Nanoparticles for Breast Cancer Theranostics," Curr. Drug Metab., vol. 20, no. 6, pp. 446–456, Jul. 2019, doi: 10.2174/1389200220666181122105043.

[115]. M. A. Subhan, "Advances with metal oxide-based nanoparticles as MDR metastatic breast cancer therapeutics and diagnostics," RSC Adv., vol. 12, no. 51, pp. 32956–32978, 2022, doi: 10.1039/D2RA02005J.

[116]. M. Xie et al., "Surface Engineering of Magnetic Iron Oxide Nanoparticles for Breast Cancer Diagnostics and Drug Delivery," Int. J. Nanomedicine, vol. Volume 19, pp. 8437–8461, Aug. 2024, doi: 10.2147/IJN.S477652.

[117]. J. Halder et al., "Trends in iron oxide nanoparticles: a nano-platform for theranostic application in breast cancer," J. Drug Target., pp. 1–21, Jul. 2022, doi: 10.1080/1061186X.2022.2095389.

[118]. H. Hosseinkazemi et al., "Applications of Iron Oxide Nanoparticles against Breast Cancer," J. Nanomater., vol. 2022, no. 1, p. 6493458, Jan. 2022, doi: 10.1155/2022/6493458.

[119]. N. Srivastava, B. Chudasama, and M. Baranwal, "Advancement in magnetic hyperthermia-based targeted therapy for cancer treatment," Biointerphases, vol. 18, no. 6, p. 060801, Nov. 2023, doi: 10.1116/6.0003079.

[120]. D. Zhi, T. Yang, J. Yang, S. Fu, and S. Zhang, "Targeting strategies for superparamagnetic iron oxide nanoparticles in cancer therapy," Acta Biomater., vol. 102, pp. 13–34, Jan. 2020, doi: 10.1016/j.actbio.2019.11.027.

[121]. J. Halder et al., "Trends in iron oxide nanoparticles: a nano-platform for theranostic application in breast cancer," J. Drug Target., pp. 1–21, Jul. 2022, doi: 10.1080/1061186X.2022.2095389.

[122]. Q. Mu et al., "Iron oxide nanoparticle targeted chemo-immunotherapy for triple negative breast cancer," Mater. Today, vol. 50, pp. 149–169, Nov. 2021, doi: 10.1016/j.mattod.2021.08.002.

[123]. V. Mulens-Arias, J. M. Rojas, and D. F. Barber, "The Use of Iron Oxide Nanoparticles to Reprogram Macrophage Responses and the Immunological Tumor Microenvironment," Front. Immunol., vol. 12, p. 693709, Jun. 2021, doi: 10.3389/fimmu.2021.693709.

[124]. C. S. Nascimento, É. A. R. Alves, C. P. De Melo, R. Corrêa-Oliveira, and C. E. Calzavara-Silva, "Immunotherapy for Cancer: Effects of Iron Oxide Nanoparticles on Polarization of Tumor-Associated Macrophages," Nanomed., vol. 16, no. 29, pp. 2633–2650, Dec. 2021, doi: 10.2217/nnm-2021-0255.

[125]. S. Chung, R. A. Revia, and M. Zhang, "Iron oxide nanoparticles for immune cell labeling and cancer immunotherapy," Nanoscale Horiz., vol. 6, no. 9, pp. 696–717, 2021, doi: 10.1039/D1NH00179E.

[126]. J. Halder et al., "Trends in iron oxide nanoparticles: a nano-platform for theranostic application in breast cancer," J. Drug Target., pp. 1–21, Jul. 2022, doi: 10.1080/1061186X.2022.2095389.

[127]. W. Liu et al., "Transition Metal Oxide Nanomaterials: New Weapons to Boost Anti-Tumor Immunity Cycle," Nanomaterials, vol. 14, no. 13, p. 1064, Jun. 2024, doi: 10.3390/nano14131064.

[128]. Q. Mu et al., "Iron oxide nanoparticle targeted chemo-immunotherapy for triple negative breast cancer," Mater. Today, vol. 50, pp. 149–169, Nov. 2021, doi: 10.1016/j.mattod.2021.08.002.

[129]. V. Mulens-Arias, J. M. Rojas, and D. F. Barber, "The Use of Iron Oxide Nanoparticles to Reprogram Macrophage Responses and the Immunological Tumor Microenvironment," Front. Immunol., vol. 12, p. 693709, Jun. 2021, doi: 10.3389/fimmu.2021.693709.

[130]. P. B. Balakrishnan, E. E. Sweeney, A. S. Ramanujam, and R. Fernandes, "Photothermal therapies to improve immune checkpoint blockade for cancer," Int. J. Hyperthermia, vol. 37, no. 3, pp. 34–49, Dec. 2020, doi: 10.1080/02656736.2020.1797190.

[131]. H. Cheng, H. Tsao, C. Chiang, and S. Chen, "Advances in Magnetic Nanoparticle-Mediated

Cancer Immune-Theranostics," Adv. Healthc. Mater., vol. 10, no. 1, p. 2001451, Jan. 2021, doi: 10.1002/adhm.202001451.

[132]. C. Cremolini, E. Vitale, R. Rastaldo, and C. Giachino, "Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy," Nanomaterials, vol. 11, no. 3, p. 661, Mar. 2021, doi: 10.3390/nano11030661.

[133]. A. N. Al-Thani, A. G. Jan, M. Abbas, M. Geetha, and K. K. Sadasivuni, "Nanoparticles in cancer theragnostic and drug delivery: A comprehensive review," Life Sci., vol. 352, p. 122899, Sep. 2024, doi: 10.1016/j.lfs.2024.122899.

[134]. E. Aram et al., "Smart and Multi-Functional Magnetic Nanoparticles for Cancer Treatment Applications: Clinical Challenges and Future Prospects," Nanomaterials, vol. 12, no. 20, p. 3567, Oct. 2022, doi: 10.3390/nano12203567.

[135]. S. Chung, R. A. Revia, and M. Zhang, "Iron oxide nanoparticles for immune cell labeling and cancer immunotherapy," Nanoscale Horiz., vol. 6, no. 9, pp. 696–717, 2021, doi: 10.1039/D1NH00179E.

[136]. N. Lee, D. Yoo, D. Ling, M. H. Cho, T. Hyeon, and J. Cheon, "Iron Oxide Based Nanoparticles for Multimodal Imaging and Magnetoresponsive Therapy," Chem. Rev., vol. 115, no. 19, pp. 10637–10689, Oct. 2015, doi: 10.1021/acs.chemrev.5b00112.

[137]. X. Yan, S. Li, H. Yan, C. Yu, and F. Liu, "IONPs-Based Medical Imaging in Cancer Care: Moving Beyond Traditional Diagnosis and Therapeutic Assessment," Int. J. Nanomedicine, vol. Volume 18, pp. 1741–1763, Apr. 2023, doi: 10.2147/IJN.S399047.

[138]. J. E. Ogbezode, U. S. Ezealigo, A. Bello, V. C. Anye, and A. P. Onwualu, "A narrative review of the synthesis, characterization, and applications of iron oxide nanoparticles," Discov. Nano, vol. 18, no. 1, p. 125, Oct. 2023, doi: 10.1186/s11671-023-03898-2.

[139]. M. Salehirozveh, P. Dehghani, and I. Mijakovic, "Synthesis, Functionalization, and Biomedical Applications of Iron Oxide Nanoparticles (IONPs)," J. Funct. Biomater., vol. 15, no. 11, p. 340, Nov. 2024, doi: 10.3390/jfb15110340.

[140]. M. T. Yassin, F. O. Al-Otibi, S. A. Al-Sahli, M. S. El-Wetidy, and S. Mohamed, "Metal Oxide Nanoparticles as Efficient Nanocarriers for Targeted Cancer Therapy: Addressing Chemotherapy-Induced Disabilities," Cancers, vol. 16, no. 24, p. 4234, Dec. 2024, doi: 10.3390/cancers16244234.

[141]. J. B. Oehler, W. Rajapaksha, and H. Albrecht, "Emerging Applications of Nanoparticles in the Diagnosis and Treatment of Breast Cancer," J. Pers. Med., vol. 14, no. 7, p. 723, Jul. 2024, doi: 10.3390/jpm14070723.

[142]. P. Singh et al., "Advanced Nanomaterials for Cancer Therapy: Gold, Silver, and Iron Oxide Nanoparticles in Oncological Applications," Adv. Healthc. Mater., vol. 14, no. 4, p. 2403059, Feb. 2025, doi: 10.1002/adhm.202403059.

[143]. D. Tripathi, P. Pandey, S. Sharma, A. K. Rai, and M. Prabhu B.H., "Advances in nanomaterials for precision drug delivery: Insights into pharmacokinetics and toxicity," BioImpacts, p. 1, Nov. 2024, doi: 10.34172/bi.30573.

[144]. R. Soomro, M. Abdelmonem, A. D. Meli, M. Panhwar, and C. A. Che Abdullah, "A novel plant-based approach for synthesis of iron oxide nanoparticles and cancer therapy," Discov. Chem., vol. 2, no. 1, p. 25, Feb. 2025, doi: 10.1007/s44371-025-00091-5.

[145]. J. Zhang, T. Zhang, and J. Gao, "Biocompatible Iron Oxide Nanoparticles for Targeted Cancer Gene Therapy: A Review," Nanomaterials, vol. 12, no. 19, p. 3323, Sep. 2022, doi: 10.3390/nano12193323.

[146]. S. Bauri, S. Tripathi, A. M. Choudhury, S. S. Mandal, H. Raj, and P. Maiti, "Nanomaterials as Theranostic Agents for Cancer Therapy," ACS Appl. Nano Mater., vol. 6, no. 23, pp. 21462–21495, Dec. 2023, doi: 10.1021/acsanm.3c04235.

[147]. A. Mhaske, S. Dighe, S. Ghosalkar, V. Tanna, P. Ravikumar, and S. P. Sawarkar, "Limitations of Current Cancer Theranostics," in Cancer Nanotheranostics, M. Saravanan and H. Barabadi, Eds., in Nanotechnology in the Life Sciences. , Cham: Springer International Publishing, 2021, pp. 305–332. doi: 10.1007/978-3-030-76263-6_12.

[148]. N. Parvin, V. Kumar, T. K. Mandal, and S. W. Joo, "Advancements in Nanoporous Materials for Biomedical Imaging and Diagnostics," J. Funct. Biomater., vol. 15, no. 8, p. 226, Aug. 2024, doi: 10.3390/jfb15080226.

[149]. A. Prina-Mello, "Multiparametric Preclinical Assessment of Theranostics Materials," in Handbook of Nanomaterials for Cancer Theranostics, Elsevier, 2018, pp. 517–535. doi: 10.1016/B978-0-12-813339-2.00017-7.

[150]. V. Sachdeva, A. Monga, R. Vashisht, D. Singh, A. Singh, and N. Bedi, "Iron Oxide Nanoparticles: The precise strategy for targeted delivery of genes, oligonucleotides and peptides in cancer therapy," J. Drug Deliv. Sci. Technol., vol. 74, p. 103585, Aug. 2022, doi: 10.1016/j.jddst.2022.103585.

[151]. M. Salehirozveh, P. Dehghani, and I. Mijakovic, "Synthesis, Functionalization, and Biomedical Applications of Iron Oxide Nanoparticles (IONPs)," J. Funct. Biomater., vol. 15, no. 11, p. 340, Nov. 2024, doi: 10.3390/jfb15110340.

[152]. R. Soomro, M. Abdelmonem, A. D. Meli, M. Panhwar, and C. A. Che Abdullah, "A novel plant-based approach for synthesis of iron oxide nanoparticles and cancer therapy," Discov. Chem., vol. 2, no. 1, p. 25, Feb. 2025, doi: 10.1007/s44371-025-00091-5.

[153]. A. N. Al-Thani, A. G. Jan, M. Abbas, M. Geetha, and K. K. Sadasivuni, "Nanoparticles in cancer theragnostic and drug delivery: A comprehensive review," Life Sci., vol. 352, p. 122899, Sep. 2024, doi: 10.1016/j.lfs.2024.122899.

[154]. J. B. Oehler, W. Rajapaksha, and H. Albrecht, "Emerging Applications of Nanoparticles in the Diagnosis and Treatment of Breast Cancer," J. Pers. Med., vol. 14, no. 7, p. 723, Jul. 2024, doi: 10.3390/jpm14070723.

[155]. P. Singh et al., "Advanced Nanomaterials for Cancer Therapy: Gold, Silver, and Iron Oxide Nanoparticles in Oncological Applications," Adv. Healthc. Mater., vol. 14, no. 4, p. 2403059, Feb. 2025, doi: 10.1002/adhm.202403059.

[156]. P. Chambial, N. Thakur, A. Sood, M. Saeed, and I. Ahmad, "Sequential catalytic nanomedicinal utilization for synergistic drug delivery application in cancer nanotechnology," J. Mol. Struct., vol. 1312, p. 138388, Sep. 2024, doi: 10.1016/j.molstruc.2024.138388.

[157]. N. Desai, V. Chavda, T. R. R. Singh, N. D. Thorat, and L. K. Vora, "Cancer Nanovaccines: Nanomaterials and Clinical Perspectives," Small, vol. 20, no. 35, p. 2401631, Aug. 2024, doi: 10.1002/smll.202401631.

[158]. N. Parvin, V. Kumar, T. K. Mandal, and S. W. Joo, "Advancements in Nanoporous Materials for Biomedical Imaging and Diagnostics," J. Funct. Biomater., vol. 15, no. 8, p. 226, Aug. 2024, doi: 10.3390/jfb15080226.

[159]. B. Tawiah, E. A. Ofori, and S. C. George, "Nanotechnology in Societal Development," in Nanotechnology in Societal Development, S. C. George and B. Tawiah, Eds., in Advanced Technologies and Societal Change. , Singapore: Springer Nature Singapore, 2024, pp. 1–64. doi: 10.1007/978-981-97-6184-5_1.

[160]. A. N. Al-Thani, A. G. Jan, M. Abbas, M. Geetha, and K. K. Sadasivuni, "Nanoparticles in

cancer theragnostic and drug delivery: A comprehensive review," Life Sci., vol. 352, p. 122899, Sep. 2024, doi: 10.1016/j.lfs.2024.122899.

[161]. B. Govindan, M. A. Sabri, A. Hai, F. Banat, and M. A. Haija, "A Review of Advanced Multifunctional Magnetic Nanostructures for Cancer Diagnosis and Therapy Integrated into an Artificial Intelligence Approach," Pharmaceutics, vol. 15, no. 3, p. 868, Mar. 2023, doi: 10.3390/pharmaceutics15030868.

[162]. J. B. Oehler, W. Rajapaksha, and H. Albrecht, "Emerging Applications of Nanoparticles in the Diagnosis and Treatment of Breast Cancer," J. Pers. Med., vol. 14, no. 7, p. 723, Jul. 2024, doi: 10.3390/jpm14070723.

[163]. Chrysoula Kokotidou, Sara H. Mejías, and Evangelos Georgilis, "Protein- and Peptide-Inorganic Nanoparticles as Theranostic Vehicles," in Functional Materials in Biomedical Applications, 1st ed., 2023, p. 61.

[164]. M. T. Yassin, F. O. Al-Otibi, S. A. Al-Sahli, M. S. El-Wetidy, and S. Mohamed, "Metal Oxide Nanoparticles as Efficient Nanocarriers for Targeted Cancer Therapy: Addressing Chemotherapy-Induced Disabilities," Cancers, vol. 16, no. 24, p. 4234, Dec. 2024, doi: 10.3390/cancers16244234.

[165]. M. Bhange and D. Telange, "Convergence of nanotechnology and artificial intelligence in the fight against liver cancer: a comprehensive review," Discov. Oncol., vol. 16, no. 1, p. 77, Jan. 2025, doi: 10.1007/s12672-025-01821-y.

[166]. S. Raikwar et al., "Opportunities in combinational chemo-immunotherapy for breast cancer using nanotechnology: an emerging landscape," Expert Opin. Drug Deliv., vol. 19, no. 3, pp. 247–268, Mar. 2022, doi: 10.1080/17425247.2022.2044785.

[167]. P. Singh et al., "Advanced Nanomaterials for Cancer Therapy: Gold, Silver, and Iron Oxide Nanoparticles in Oncological Applications," Adv. Healthc. Mater., vol. 14, no. 4, p. 2403059, Feb. 2025, doi: 10.1002/adhm.202403059.

[168]. D. Xie, L. Sun, M. Wu, and Q. Li, "From detection to elimination: iron-based nanomaterials driving tumor imaging and advanced therapies," Front. Oncol., vol. 15, p. 1536779, Feb. 2025, doi: 10.3389/fonc.2025.1536779.

[169]. M. Xie et al., "Surface Engineering of Magnetic Iron Oxide Nanoparticles for Breast Cancer Diagnostics and Drug Delivery," Int. J. Nanomedicine, vol. Volume 19, pp. 8437–8461, Aug. 2024, doi: 10.2147/IJN.S477652.